|
gptkbp:instanceOf
|
gptkb:company
|
|
gptkbp:acquiredBy
|
gptkb:Covance
|
|
gptkbp:acquisitionYear
|
gptkb:Covance
2015
|
|
gptkbp:CEO
|
gptkb:Adam_H._Schechter
|
|
gptkbp:competitor
|
gptkb:Quest_Diagnostics
gptkb:BioReference_Laboratories
gptkb:Mayo_Clinic_Laboratories
|
|
gptkbp:divested
|
2023
Labcorp Drug Development (2023)
|
|
gptkbp:founded
|
1978
|
|
gptkbp:founder
|
gptkb:Reynolds_Medical_Laboratory
|
|
gptkbp:fullName
|
gptkb:Laboratory_Corporation_of_America_Holdings
|
|
gptkbp:headquartersLocation
|
gptkb:Burlington,_North_Carolina,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Labcorp
|
|
gptkbp:industry
|
healthcare
diagnostics
|
|
gptkbp:ISIN
|
US50540R4092
|
|
gptkbp:laboratoryNetwork
|
gptkb:Canada
gptkb:United_Kingdom
gptkb:United_States
other international locations
|
|
gptkbp:listedOn
|
gptkb:S&P_500
|
|
gptkbp:memberOf
|
gptkb:Fortune_500
|
|
gptkbp:NAICS
|
621511
|
|
gptkbp:notableProduct
|
COVID-19 testing
genetic testing
oncology diagnostics
|
|
gptkbp:numberOfEmployees
|
~78,000
|
|
gptkbp:numberOfLocations
|
over 2,000 patient service centers
|
|
gptkbp:parentCompany
|
independent
|
|
gptkbp:rank
|
Fortune 500 (2023): #274
|
|
gptkbp:revenue
|
$14.88 billion (2023)
|
|
gptkbp:servesArea
|
worldwide
|
|
gptkbp:services
|
clinical laboratory services
drug development services
|
|
gptkbp:SIC
|
8071
|
|
gptkbp:specialty
|
clinical trials
genomics
toxicology
esoteric testing
routine testing
|
|
gptkbp:stockSymbol
|
gptkb:LH
|
|
gptkbp:subsidiary
|
gptkb:Covance
gptkb:Labcorp_Drug_Development
|
|
gptkbp:tradedOn
|
gptkb:NYSE
|
|
gptkbp:type
|
gptkb:public_company
|
|
gptkbp:website
|
https://www.labcorp.com/
|
|
gptkbp:bfsParent
|
gptkb:Adam_H._Schechter
gptkb:Covance
gptkb:Ovia
|
|
gptkbp:bfsLayer
|
7
|